Jane Lian to Disease Progression
This is a "connection" page, showing publications Jane Lian has written about Disease Progression.
Connection Strength
0.541
-
Farina NH, Zingiryan A, Akech JA, Callahan CJ, Lu H, Stein JL, Languino LR, Stein GS, Lian JB. A microRNA/Runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice. Oncotarget. 2016 Oct 25; 7(43):70462-70474.
Score: 0.099
-
Taipaleenm?ki H, Browne G, Akech J, Zustin J, van Wijnen AJ, Stein JL, Hesse E, Stein GS, Lian JB. Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease. Cancer Res. 2015 Apr 01; 75(7):1433-44.
Score: 0.088
-
Zhang X, Akech J, Browne G, Russell S, Wixted JJ, Stein JL, Stein GS, Lian JB. Runx2-Smad signaling impacts the progression of tumor-induced bone disease. Int J Cancer. 2015 Mar 15; 136(6):1321-32.
Score: 0.085
-
Browne G, Taipaleenm?ki H, Stein GS, Stein JL, Lian JB. MicroRNAs in the control of metastatic bone disease. Trends Endocrinol Metab. 2014 Jun; 25(6):320-7.
Score: 0.083
-
Farina NH, Zingiryan A, Vrolijk MA, Perrapato SD, Ades S, Stein GS, Lian JB, Landry CC. Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention. J Cell Physiol. 2018 09; 233(9):6408-6417.
Score: 0.027
-
Fritz AJ, Ghule PN, Boyd JR, Tye CE, Page NA, Hong D, Shirley DJ, Weinheimer AS, Barutcu AR, Gerrard DL, Frietze S, van Wijnen AJ, Zaidi SK, Imbalzano AN, Lian JB, Stein JL, Stein GS. Intranuclear and higher-order chromatin organization of the major histone gene cluster in breast cancer. J Cell Physiol. 2018 Feb; 233(2):1278-1290.
Score: 0.026
-
Tracy KM, Tye CE, Page NA, Fritz AJ, Stein JL, Lian JB, Stein GS. Selective expression of long non-coding RNAs in a breast cancer cell progression model. J Cell Physiol. 2018 Feb; 233(2):1291-1299.
Score: 0.026
-
McGee-Lawrence ME, Carpio LR, Bradley EW, Dudakovic A, Lian JB, van Wijnen AJ, Kakar S, Hsu W, Westendorf JJ. Runx2 is required for early stages of endochondral bone formation but delays final stages of bone repair in Axin2-deficient mice. Bone. 2014 Sep; 66:277-86.
Score: 0.021
-
Zaidi SK, Grandy RA, Lopez-Camacho C, Montecino M, van Wijnen AJ, Lian JB, Stein JL, Stein GS. Bookmarking target genes in mitosis: a shared epigenetic trait of phenotypic transcription factors and oncogenes? Cancer Res. 2014 Jan 15; 74(2):420-5.
Score: 0.020
-
Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, Volinia S, Stein GS, Croce CM, Lian JB, Aqeilan RI. miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 2012 Apr 01; 72(7):1865-77.
Score: 0.018
-
Kang BH, Siegelin MD, Plescia J, Raskett CM, Garlick DS, Dohi T, Lian JB, Stein GS, Languino LR, Altieri DC. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res. 2010 Oct 01; 16(19):4779-88.
Score: 0.016
-
Kurek KC, Del Mare S, Salah Z, Abdeen S, Sadiq H, Lee SH, Gaudio E, Zanesi N, Jones KB, DeYoung B, Amir G, Gebhardt M, Warman M, Stein GS, Stein JL, Lian JB, Aqeilan RI. Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res. 2010 Jul 01; 70(13):5577-86.
Score: 0.016
-
Pratap J, Lian JB, Stein GS. Metastatic bone disease: role of transcription factors and future targets. Bone. 2011 Jan; 48(1):30-6.
Score: 0.016